Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics develops cancer drugs that deliver targeted radiation to tumors, paired with imaging tools to guide treatment. It last closed at $0.75 on Nov 20, down 3.85% on the day. The next earnings report for CATX is expected around Mon, Mar 15, 2027, after the close. For the quarter ended Sep 2026, CATX reported EPS of -$0.27. Over its last 8 reports the stock moved an average of 7.9% the session after earnings. Over the last 12 months CATX insiders bought $175K of stock on the open market and sold $1.6M, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From CATX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on CATX
Technical AnalysisPrices may be delayed
The stock is 24% below its 20 day and 151% below its 50 day average. It is 344% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the 52 week low at $0.73, and the nearest resistance the Pivot at $0.76.
| RSI (14) | 25.36 | Oversold below 30 | Oversold |
| MACD | -0.33 | Above its signal line | Bullish |
| Stochastic | 7.0 | Near the bottom of its range | Oversold |
| ADX (14) | 50.5 | Strong downtrend | |
| Williams %R | -91.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -91.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −10.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.14 | Typical daily range, 18.8% of price |
| RSI (14) | 24.64 | Oversold below 30 | Oversold |
| MACD | -0.66 | Below its signal line | Bearish |
| Stochastic | 3.0 | Near the bottom of its range | Oversold |
| ADX (14) | 23.4 | Weak trend | |
| Williams %R | -99.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -162.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −73.2% | Change over 10 sessions | Bearish |
| ATR (14) | $0.48 | Typical daily range, 63.8% of price |
What happened before
See how CATX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CATX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.
Whale Options FlowPrices may be delayed
90DNo whale options trades in CATX in the last 90 days.
CATX Institutional Ownership
Full report →- ●58 buying vs 59 selling
- ▼Held by funds -7.7 pts
- ▼Funds holding -12
- ▲Superinvestors: 4 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 120 | 132 | −9.1% |
| In funds' top 10 | 3 | 3 | 0.0% |
| Held by funds | 66.5% | 74.2% | −7.7 pts |
| New / increased | 14 / 44 | 23 / 59 | −29.3% |
| Reduced / sold out | 35 / 24 | 27 / 30 | +3.5% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
CATX Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 18 | Robert F Williamson IIIDirector | Buy | 15,000 | $0.80 | $12K |
| Nov 17 | Robert F Williamson IIIDirector | Buy | 25,000 | $0.84 | $21K |
| Nov 16 | Frank MorichDirector | Buy | 15,000 | $0.94 | $14K |
| Nov 12 | Lori A WoodsDirector | Buy | 23,750 | $0.84 | $20K |
| Nov 12 | Robert F Williamson IIIDirector | Buy | 24,898 | $0.84 | $21K |
| Nov 12 | Frank MorichDirector | Buy | 15,000 | $1.00 | $15K |
From SEC Form 4 filings by CATX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CATX is in one of them and how their past CATX trades turned out.
CATX News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CATX in an article yet. Here's the latest on the wider market.
- Perspective Therapeutics Provides Recent Business Highlights and
- Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in
- Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
- Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
About Perspective Therapeutics
Perspective Therapeutics is a radiopharmaceutical development company based in Seattle, Washington. It is developing cancer treatments that attach a radioactive isotope known as lead 212 to targeting molecules, which are designed to carry radiation directly to cancer cells. The company also develops imaging agents using a related isotope so that doctors can locate tumors before treatment. Its lead candidates are in clinical trials in the United States for neuroendocrine tumors, melanoma and other solid tumors. The intended users of these treatments are cancer patients and the clinicians who treat them, and the company is building its own manufacturing capacity.
- Headquarters
- Seattle, WA



